VBIO

Business Context and Reporting Period

Company: Tivic Health Systems, Inc. (TIVC)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2025
Business Overview: Tivic executed a strategic pivot in 2025 from a consumer healthtech company to a late-stage biopharmaceutical firm. The company exited its ClearUP consumer device business and non-invasive cervical vagus nerve stimulation platform to focus exclusively on its TLR5 agonist franchise, led by Entolimod (for Acute Radiation Syndrome and oncology indications) and Entolasta. In December 2025, Tivic acquired the assets of Scorpius Holdings to form Velocity Bioworks, a wholly-owned Contract Development and Manufacturing Organization (CDMO).

Key Financial Metrics

Note: Revenue from the discontinued ClearUP business was $0.4 million in 2025 and $0.8 million in 2024. The company has no product revenue from continuing operations.

Material Changes vs. Prior Period

• Strategic Pivot: Complete exit from the consumer healthtech business (ClearUP) and bioelectronic device development. Resources are now fully allocated to the biopharmaceutical pipeline and CDMO operations.
• Acquisition: Acquired Scorpius Holdings assets in December 2025 to establish Velocity Bioworks, adding $12.6 million in property and equipment and $3.5 million in goodwill to the balance sheet.
• Licensing: Acquired exclusive worldwide license rights to Entolimod and Entolasta from Statera Biopharma in February 2025, including rights for Acute Radiation Syndrome (ARS) and neutropenia.
• Capital Structure: Raised approximately $18.5 million in net proceeds during 2025 through the issuance of Series B and Series C Preferred Stock, common stock, and a $16.3 million Senior Secured Convertible Note.
• Leadership Change: Michael K. Handley was appointed CEO in March 2026, succeeding Jennifer Ernst.

Guidance, Outlook, and Risks

Outlook and Management Commentary

• Regulatory Pathway: The company is advancing Entolimod toward a Biologics License Application (BLA) under the FDA Animal Rule for ARS. It is also preparing Phase 2 studies for oncology indications (neutropenia, thrombocytopenia, mucositis).
• Government Engagement: Active engagement with BARDA, DoD/DTRA, and the FDA regarding potential procurement for the Strategic National Stockpile (SNS).
• Manufacturing: Velocity Bioworks demonstrated a 200-fold manufacturing scale-up for Entolimod in January 2026.

Risks and Contingencies

• Going Concern: The filing states that cash and financial resources may be insufficient to meet anticipated needs for the next twelve months, raising substantial doubt about the company's ability to continue as a going concern.
• Nasdaq Compliance: Received notice in March 2026 of non-compliance with the Nasdaq Minimum Bid Price Requirement (stock price below $1.00 for 30 consecutive days). The company has 180 days to regain compliance or face delisting.
• Internal Controls: Identified a material weakness in internal control over financial reporting due to small accounting team size and staff turnover.
• Financing Needs: The company expects to incur substantial additional operating losses and will need to raise additional capital to fund clinical trials and operations.

Investor Verification Checklist

• Liquidity Runway: Verify the sufficiency of the $12.6 million cash balance against the stated burn rate and the "substantial doubt" regarding going concern status.
• Nasdaq Status: Monitor the stock price to ensure it meets the $1.00 minimum bid price requirement for 10 consecutive days before September 15, 2026, to avoid delisting.
• Debt Covenants: Review the terms of the $16.3 million Senior Secured Convertible Note, specifically regarding conversion floors, interest rates, and potential default triggers (e.g., key person departure).
• Regulatory Milestones: Track progress on the BLA submission for Entolimod under the Animal Rule and the initiation of Phase 2 oncology trials.
• Internal Controls: Assess the remediation plan for the material weakness in internal controls over financial reporting.